Leerink Partnrs Has Strong Forecast for WVE FY2026 Earnings

Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) - Stock analysts at Leerink Partnrs boosted their FY2026 EPS estimates for shares of Wave Life Sciences in a report released on Tuesday, April 29th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings of ($1.11) per share for the year, up from their previous estimate of ($1.12). The consensus estimate for Wave Life Sciences' current full-year earnings is ($1.14) per share.

WVE has been the topic of a number of other research reports. Jefferies Financial Group initiated coverage on shares of Wave Life Sciences in a research report on Tuesday, February 25th. They issued a "buy" rating and a $26.00 price objective on the stock. StockNews.com upgraded Wave Life Sciences from a "sell" rating to a "hold" rating in a report on Saturday, March 8th. Cantor Fitzgerald initiated coverage on Wave Life Sciences in a report on Tuesday, April 29th. They issued an "overweight" rating and a $10.00 price objective for the company. HC Wainwright reiterated a "buy" rating and issued a $22.00 price objective on shares of Wave Life Sciences in a research report on Wednesday, March 26th. Finally, Wedbush assumed coverage on Wave Life Sciences in a report on Tuesday, April 8th. They set an "outperform" rating and a $18.00 target price for the company. Two research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $21.17.

Wave Life Sciences Price Performance

WVE traded down $0.37 during trading on Thursday, reaching $7.73. The company had a trading volume of 2,877,166 shares, compared to its average volume of 1,247,796. The company has a market cap of $1.19 billion, a P/E ratio of -6.96 and a beta of -0.91. Wave Life Sciences has a 12 month low of $4.25 and a 12 month high of $16.74. The business's fifty day moving average price is $8.16 and its 200 day moving average price is $11.42.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last posted its quarterly earnings results on Tuesday, March 4th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.34. The business had revenue of $83.75 million for the quarter, compared to analysts' expectations of $25.60 million. Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%.

Hedge Funds Weigh In On Wave Life Sciences

A number of hedge funds have recently made changes to their positions in WVE. Price T Rowe Associates Inc. MD increased its holdings in shares of Wave Life Sciences by 63.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,098,866 shares of the company's stock worth $63,074,000 after buying an additional 1,972,262 shares during the last quarter. Loomis Sayles & Co. L P acquired a new stake in Wave Life Sciences in the fourth quarter valued at $20,545,000. Polar Capital Holdings Plc acquired a new stake in shares of Wave Life Sciences during the 4th quarter worth about $12,370,000. MPM Bioimpact LLC boosted its holdings in shares of Wave Life Sciences by 138.5% in the 4th quarter. MPM Bioimpact LLC now owns 1,489,237 shares of the company's stock valued at $18,422,000 after buying an additional 864,766 shares in the last quarter. Finally, Driehaus Capital Management LLC boosted its stake in Wave Life Sciences by 14.6% in the fourth quarter. Driehaus Capital Management LLC now owns 6,712,449 shares of the company's stock valued at $83,033,000 after acquiring an additional 853,589 shares in the last quarter. Institutional investors and hedge funds own 89.73% of the company's stock.

Insider Buying and Selling

In other news, Director Christian O. Henry sold 10,500 shares of the business's stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $9.77, for a total value of $102,585.00. Following the completion of the sale, the director now directly owns 16,115 shares in the company, valued at $157,443.55. The trade was a 39.45 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Paul Bolno sold 169,025 shares of the company's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $9.57, for a total transaction of $1,617,569.25. Following the transaction, the chief executive officer now owns 338,351 shares of the company's stock, valued at $3,238,019.07. This represents a 33.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 29.10% of the stock is owned by company insiders.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.